Approval · Notice of Compliance 32247 · 2023
AZITHROMYCIN: Notice of Compliance 32247
Issued December 1, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32247
- Date
- December 1, 2023
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZITHROMYCIN | Not yet assigned | — |
| PMS-AZITHROMYCIN | Not yet assigned | — |
Medicinal ingredients
- AZITHROMYCIN 100 MG per 5ML
- AZITHROMYCIN 200 MG per 5ML
- AZITHROMYCIN 250 MG per TAB
- AZITHROMYCIN 600 MG per TAB